• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Daniel Petrylak Explains PD-1, PD-L1 Expression in Bladder Cancer Treatment

Video

New study results being presented at the American Society of Clinical Oncology's annual meeting in Chicago found that the PD-1 and PD-L1 biomarkers can be used to determine response and resistance, explained Daniel P. Petrylak, MD.

New study results being presented at the American Society of Clinical Oncology's annual meeting in Chicago found that the PD-1 and PD-L1 biomarkers can be used to determine response and resistance, explained Daniel P. Petrylak, MD, professor of medicine (medical oncology) and of urology at the Yale Cancer Center. He will be presenting the results of a trial on PD-1 and PD-L1 expression in bladder cancer.

"We need to diligently assess tissue in these patients to help understand the marker pattern and how it can be used to treat them," he said.

Related Videos
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Mabel Mardones, MD.
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester
Dr Bonnie Qin
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.